Accelerated approvals are driving a greater reliance on post-approval pharmacovigilance, but current PV processes are often slow, error-prone, and heavily reliant on human capacity.
In this webinar Andrew Rut joins Dr. Andree Bates, CEO of Eularis, to discuss why 'technology is the key to unlocking safety signals quickly and efficiently.'
